Last October, a functional medicine practitioner in Austin named Dr. Rachel Wen told me about a patient who'd been through seven rounds of antibiotics over two years for recurrent chronic sinusitis. CT scans still showed mucosal thickening. Cultures kept growing the same Staph species. "By the time he came to me," she said, "he'd basically accepted that he was going to live with this forever." She added LL 37 as an adjunct to a targeted antibiotic course. Eight weeks later, his symptom scores had dropped by roughly 60%, and a follow-up CT was markedly improved. One patient, no control group, no blinding. But the case stuck with me because it illustrates why people keep circling back to this peptide.
LL 37 is the sole human cathelicidin antimicrobial peptide. It kills bacteria, fungi, and certain viruses across a broad spectrum, and it does something most antibiotics cannot: it tears apart the biofilm communities that shield chronic infections from treatment. That biofilm-disrupting property is the entire reason LL 37 keeps showing up in chronic infection conversations, and it's the reason this article exists.
Why Biofilms Are the Real Enemy
Think of a biofilm like a fortified city. Individual bacteria floating around in your bloodstream (planktonic cells) are foot soldiers in an open field. An antibiotic picks them off easily. But once those same organisms hunker down, secrete an extracellular matrix, build communication networks via quorum sensing, and establish dormant "persister" cells deep within the structure, you're not fighting an infection anymore. You're laying siege.
This is the reality behind a lot of chronic infections. Pseudomonas aeruginosa colonies in cystic fibrosis airways. Staphylococcus aureus in chronic wounds and on prosthetic hardware. The polymicrobial sludge in chronic sinusitis. Recurrent UTIs that return like clockwork six weeks after the last fluoroquinolone course.
Antibiotics designed for planktonic bacteria struggle against these structures. The matrix blocks drug penetration. Dormant cells inside aren't metabolically active enough for most antibiotics to touch. And the biofilm environment actively selects for persister phenotypes that shrug off standard therapy.
The result: patients cycle through antibiotic after antibiotic, each course killing the easy targets while the biofilm community persists.
LL 37 attacks this problem differently. It interferes with biofilm formation, disrupts established biofilm architecture, and kills organisms through membrane disruption rather than the metabolic pathways most antibiotics target. That combination is what makes it genuinely interesting, not just another bench curiosity.
What the Research Actually Shows
The strongest data comes from in vitro work and animal models. Human clinical evidence is thin, mostly small case series and adjunct protocols, not controlled trials. That caveat matters, but so does the consistency of what's been observed.
Pseudomonas. Overhage and colleagues published foundational work demonstrating that LL 37 both prevents Pseudomonas aeruginosa biofilm formation and breaks down existing biofilms in vitro. Subsequent research has replicated this across multiple Pseudomonas strains and clinical isolates.
Staph, including MRSA. Multiple groups have shown LL 37 activity against Staphylococcus biofilms, including methicillin-resistant strains. The mechanism seems to combine direct membrane disruption with degradation of matrix integrity and interference with quorum-sensing signals.
Mixed-species biofilms. Research has demonstrated activity against polymicrobial biofilms relevant to chronic sinusitis and chronic wound contexts, which matters because real-world chronic infections rarely involve a single organism acting alone.
Here's the thing: the reason resistance to LL 37 develops far more slowly than resistance to conventional antibiotics is that resisting a membrane-disrupting peptide requires fundamental changes to microbial membrane chemistry. That's a much heavier evolutionary lift than, say, acquiring a single beta-lactamase gene.
Protocols: What's Actually Being Used
Subcutaneous (systemic applications)
The typical range is 100 to 1000 mcg subcutaneous, administered 3 to 5 times per week. Most protocols start low, at 100 to 250 mcg per injection, and titrate upward based on tolerance. A standard course runs 6 to 12 weeks before formal reassessment.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Nebulized (respiratory infections)
For chronic sinopulmonary infections and cystic fibrosis-adjacent applications, nebulized delivery gets the peptide directly to affected airways. This requires specific formulation and proper nebulizer equipment. It's more specialized than subcutaneous administration and not something to improvise.
Topical (chronic wounds)
LL 37 in cream or gel preparations, applied once or twice daily directly to the wound surface. The logic is straightforward: put the biofilm disruptor where the biofilm lives.
Intranasal (sinusitis)
Direct delivery to affected mucosal surfaces in chronic sinusitis contexts. Same principle as topical wound application, different anatomy.
The First Two Weeks Can Be Rough
This is the part that catches people off guard. When you start disrupting biofilms that have been entrenched for months or years, the sudden release of microbial debris and endotoxins can trigger Herxheimer-like reactions. Fatigue, malaise, headache, and (somewhat counterintuitively) a temporary worsening of the very infection symptoms you're trying to treat.
It's not an allergic reaction. It's not the peptide causing harm. It's the biological fallout from tearing down a well-established microbial fortress. Most protocols account for this by starting at low doses (100 to 200 mcg) during the first week. If the reaction is significant, drop the dose temporarily rather than pushing through.
Most people see these reactions settle within the first week or two. If they don't, that's a conversation with your prescriber, not something to white-knuckle through on a forum protocol.
Using LL 37 Alongside Antibiotics
The most common clinical framing is adjunctive: LL 37 strips the biofilm, conventional antibiotics kill the newly exposed organisms. The peptide is the siege engine; the antibiotic is the infantry.
This combination makes mechanistic sense, and it's described in multiple protocols, but it hasn't been validated in controlled human trials. It remains a prescriber decision. Some protocols also layer in other antimicrobial or immune-modulating peptides (like Thymosin Alpha 1) on the rationale of complementary mechanisms, though again, these combinations are clinical judgment calls, not evidence-based protocols in the strict sense.
The Safety Question You Can't Skip
The most important safety consideration with LL 37 has nothing to do with injection site reactions (which do happen and respond to site rotation and slow escalation). It's the autoimmune signal.
Lande and colleagues described LL 37 complexing with self-DNA to activate plasmacytoid dendritic cells in psoriasis pathogenesis. In plain language: in some autoimmune contexts, LL 37 acts as a self-antigen, meaning your immune system can mount a response against it, and by extension, against your own tissues.
If you have psoriasis, this is a serious consideration. Not a theoretical one. The same caution applies to rosacea, where elevated endogenous cathelicidin has been implicated in disease activity.
Long-term safety data over multi-year continuous use doesn't exist. Protocols of 6 to 12 weeks have a reasonable safety profile in available reports, but extending beyond that requires ongoing clinical monitoring and honest risk-benefit conversations.
How LL 37 Fits (and Doesn't Fit) Among Other Options
LL 37 is not a replacement for conventional antibiotics in acute bacterial infections. Full stop. If you have a straightforward UTI or cellulitis, take the antibiotic.
Where LL 37 occupies a different lane is in chronic, biofilm-mediated infections where antibiotics alone have demonstrably failed. That's a much narrower use case than the internet sometimes suggests.
Compared to other antimicrobial peptides (defensins, synthetic derivatives), LL 37 has the largest research base among human cathelicidins. Compared to immune-modulating peptides like Thymosin Alpha 1, the mechanism is entirely different: LL 37 is a direct antimicrobial and biofilm disruptor, while Thymosin Alpha 1 works through immune system modulation. They're not interchangeable, and some practitioners use both.
What to Realistically Expect
Effects accumulate over weeks, not days. The first phase may feel worse, not better. The evidence base, while mechanistically compelling, consists of laboratory data, animal models, and limited human case reports rather than randomized controlled trials. And LL 37 doesn't replace proper diagnostic workup. If your chronic infection hasn't been adequately characterized (culture, sensitivity, imaging as appropriate), adding a peptide on top of an incomplete picture isn't strategy. It's hope dressed up as protocol.
My honest take: LL 37 is one of the more scientifically grounded peptides in the chronic infection space, and the biofilm disruption mechanism addresses a genuine gap in conventional treatment. But the gap between "promising in vitro data" and "proven clinical therapy" is real, and patients should walk in with clear eyes about where on that spectrum this currently sits.
Frequently Asked Questions
Does LL 37 work against antibiotic-resistant infections?
In vitro evidence demonstrates activity against methicillin-resistant Staphylococcus aureus (MRSA) and other resistant organisms. Because the mechanism (membrane disruption) is fundamentally different from the pathways most antibiotic resistance mechanisms target, cross-resistance is unlikely.
What is a Herxheimer reaction with LL 37?
A cluster of symptoms (fatigue, malaise, headache, symptom flare) in the first 1 to 2 weeks, attributed to rapid biofilm disruption and microbial die-off. Typically resolves with temporary dose reduction.
Can I use LL 37 alongside antibiotics?
Yes, this is the most common protocol framing. The combination is a prescriber decision, and the mechanistic rationale (biofilm disruption plus conventional antimicrobial kill) suggests potential additive benefit.
Is LL 37 safe for people with psoriasis?
LL 37 has been identified as a self-antigen in psoriasis pathogenesis (Lande et al.). Patients with psoriasis should discuss this specific risk with their prescriber before considering exogenous LL 37 administration.
How long should an LL 37 chronic infection course last?
Six to twelve weeks with reassessment is the standard framework. Continuation beyond that requires ongoing clinical evaluation of response and tolerability.
Does LL 37 replace antibiotics?
No. It is researched as an adjunct, particularly in biofilm-mediated chronic infections where antibiotics alone have been insufficient.
What's the typical starting dose?
Most protocols begin at 100 to 250 mcg subcutaneous per administration to assess tolerance before titrating upward.
Related Reading
- LL 37 Hub
- LL 37 Dosage Protocols
- Thymosin Alpha 1 Hub
- Best Peptides for Healing and Recovery
Compliance Footer
LL 37 is not approved by the FDA for the prevention, mitigation, treatment, or cure of any disease, including any infection. Compounded LL 37 is prepared by licensed compounding pharmacies for individual patients under a valid prescription from a licensed prescriber. Information on this page is educational and is not medical advice. Individual results vary.